Synergistic effect of a tumor-promoting phorbol ester and a hypoglycemic sulfonylurea upon insulin release.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375040 Publication Model: Print Cited Medium: Print ISSN: 0013-7227 (Print) Linking ISSN: 00137227 NLM ISO Abbreviation: Endocrinology Subsets: MEDLINE
    • Publication Information:
      Publication: 2017- : New York : Oxford University Press
      Original Publication: Los Angeles, Calif. : Association for the Study of Internal Secretions,
    • Subject Terms:
      Gliclazide/*pharmacology ; Insulin/*blood ; Phorbols/*pharmacology ; Sulfonylurea Compounds/*pharmacology ; Tetradecanoylphorbol Acetate/*pharmacology; Animals ; Calcium/pharmacology ; Drug Synergism ; Glucose/pharmacology ; Islets of Langerhans/drug effects ; Islets of Langerhans/metabolism ; Rats ; Time Factors
    • Abstract:
      The tumor-promoting phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA) and the hypoglycemic sulfonylurea gliclazide both stimulate insulin release from rat pancreatic islets incubated at a low concentration of glucose (2.8 mM). The increment in secretion rate evoked by the combination of these two secretagogues was at least 7 times higher than the sum of increments evoked by each agent alone. TPA augmented insulin release evoked by gliclazide more efficiently than that induced by glucose. The enhancing action of TPA could not be attributed solely to changes in the capacity of gliclazide to inhibit 86Rb outflow, to provoke an exchange between influent 40Ca and effluent 45Ca, or to stimulate the net uptake of 45Ca by the islets. Nevertheless, the facilitation by TPA of gliclazide-induced insulin release suggests that a biophysical interference with the handling of cations at the plasma membrane level represents the primary site of action of hypoglycemic sulfonylureas in the pancreatic B cell.
    • Accession Number:
      0 (Insulin)
      0 (Phorbols)
      0 (Sulfonylurea Compounds)
      G4PX8C4HKV (Gliclazide)
      IY9XDZ35W2 (Glucose)
      NI40JAQ945 (Tetradecanoylphorbol Acetate)
      SY7Q814VUP (Calcium)
    • Publication Date:
      Date Created: 19831101 Date Completed: 19831217 Latest Revision: 20131121
    • Publication Date:
      20240829
    • Accession Number:
      10.1210/endo-113-5-1870
    • Accession Number:
      6354699